content: UNITED STATES
  
                         SECURITIES AND EXCHANGE COMMISSION
  
                               WASHINGTON, D.C. 20549
  
                     -------------------------------------------
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
                       PURSUANT TO SECTION 13 OR 15(D) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
           Date of report (Date of earliest event reported): March 3, 2005
                                                             -------------
  
                                 CYTOGEN CORPORATION
              --------------------------------------------------------
                 (Exact Name of Registrant as Specified in Charter)
  
           Delaware                         000-14879               22-2322400
  ----------------------------      ------------------------   -------------------
  (State or Other Jurisdiction      (Commission File Number)    (I.R.S. Employer
        of Incorporation)                                      Identification No.)
  
     650 College Road East, CN 5308, Suite 3100, Princeton, NJ           08540
  ---------------------------------------------------------------    -------------
             (Address of Principal Executive Offices)                 (Zip Code)
  
         Registrant's telephone number, including area code: (609) 750-8200
                                                             --------------
  
  
  --------------------------------------------------------------------------------
            (Former Name or Former Address, if Changed Since Last Report)
  
  
       Check the  appropriate  box below if the Form 8-K  filing  is  intended  to
  simultaneously  satisfy the filing obligation of the registrant under any of the
  following provisions (see General Instruction A.2. below):
  
       |_|  Written communications  pursuant to Rule 425 under the  Securities Act
  (17 CFR 230.425)
  
       |_|  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
  CFR 240.14a-12)
  
       |_|  Pre-commencement  communications  pursuant to Rule 14d-2(b)  under the
  Exchange Act (17 CFR 240.14d-2(b))
  
       |_|  Pre-commencement  communications  pursuant to Rule 13e-4(c)  under the
  Exchange Act (17 CFR 240.13e-4(c))
  
  <PAGE>
  
  
  ITEM 8.01   OTHER EVENTS.
  
  
       On  March  3,  2005,  Advanced  Magnetics,  Inc.  and  Cytogen  Corporation
  announced that the U.S. Food and Drug Administration's  Oncologic Drugs Advisory
  Committee  (ODAC)  voted  15 to 4 to not  recommend  approval  of  the  proposed
  indication  for  Combidex(R),  Advanced  Magnetics'  investigational  functional
  molecular  imaging  agent.  In making its  recommendation,  the committee  cited
  insufficient  clinical data to support a broad indication for use of Combidex to
  differentiate  metastatic  from  non-metastatic  lymph  nodes  across all cancer
  types.
  
       Combidex  (ferumoxtran-10)  consists of iron oxide nanoparticles for use in
  conjunction with magnetic resonance imaging (MRI) to aid in the  differentiation
  of cancerous from non-cancerous lymph nodes.
  
       Combidex received an approvable letter, subject to certain conditions, from
  the FDA in June 2000. In September 2004, Advanced Magnetics submitted a complete
  response to the approvable letter. A decision by the FDA on Combidex is expected
  by the FDA-designated user fee goal date of March 30, 2005.
  
       The full text of the March 3, 2005 press release issued in connection  with
  the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K,
  and is incorporated herein by reference.  The foregoing description is qualified
  in its entirety by reference to such Exhibit.
  
  ITEM 9.01   FINANCIAL STATEMENTS AND EXHIBITS
  
  (c) Exhibits.
  
       Exhibit No.       Description
       -----------       -----------
           99.1          Press Release  of Advanced  Magnetics and  Cytogen  dated
                         March 3, 2005
  
  
  
  <PAGE>
  
  
                                     SIGNATURES
  
  
       Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
  Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
  undersigned hereunto duly authorized.
  
                                      CYTOGEN CORPORATION
  
  
  
                                      By:  /s/ William J. Thomas
                                         -----------------------------------------
                                         William J. Thomas
                                         Senior Vice President and General Counsel
  
  Dated:   March 3, 2005
  
  
  
  <PAGE>
  
  
                                    EXHIBIT INDEX
  
  
       Exhibit No.       Description
       -----------       -----------
           99.1          Press  Release of Advanced  Magnetics and  Cytogen  dated
                         March 3, 2005
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "form8-k_030305.txt", "description": "FORM 8-K FILED ON 03/03/05 COMBIDEX", "secsgml_size_bytes": 4792}]
metadata_filer: {"company-data": {"conformed-name": "CYTOGEN CORP", "cik": "0000725058", "assigned-sic": "2834", "irs-number": "222322400", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-14879", "film-number": "05657983"}, "business-address": {"street1": "650 COLLEGE RD EAST STE 3100", "city": "PRINCETON", "state": "NJ", "zip": "08540", "phone": "6099878200"}, "mail-address": {"street1": "650 COLLEGE RD EAST STE 3100", "city": "PRINCETON", "state": "NJ", "zip": "08540"}}
text: UNITED STATES
  
                         SECURITIES AND EXCHANGE COMMISSION
  
                               WASHINGTON, D.C. 20549
  
                     -------------------------------------------
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
                       PURSUANT TO SECTION 13 OR 15(D) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
           Date of report (Date of earliest event reported): March 3, 2005
                                                             -------------
  
                                 CYTOGEN CORPORATION
              --------------------------------------------------------
                 (Exact Name of Registrant as Specified in Charter)
  
           Delaware                         000-14879               22-2322400
  ----------------------------      ------------------------   -------------------
  (State or Other Jurisdiction      (Commission File Number)    (I.R.S. Employer
        of Incorporation)                                      Identification No.)
  
     650 College Road East, CN 5308, Suite 3100, Princeton, NJ           08540
  ---------------------------------------------------------------    -------------
             (Address of Principal Executive Offices)                 (Zip Code)
  
         Registrant's telephone number, including area code: (609) 750-8200
                                                             --------------
  
  --------------------------------------------------------------------------------
            (Former Name or Former Address, if Changed Since Last Report)
  
       Check the  appropriate  box below if the Form 8-K  filing  is  intended  to
  simultaneously  satisfy the filing obligation of the registrant under any of the
  following provisions (see General Instruction A.2. below):
  
       |_|  Written communications  pursuant to Rule 425 under the  Securities Act
  (17 CFR 230.425)
  
       |_|  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
  CFR 240.14a-12)
  
       |_|  Pre-commencement  communications  pursuant to Rule 14d-2(b)  under the
  Exchange Act (17 CFR 240.14d-2(b))
  
       |_|  Pre-commencement  communications  pursuant to Rule 13e-4(c)  under the
  Exchange Act (17 CFR 240.13e-4(c))
  ITEM 8.01   OTHER EVENTS.
  
       On  March  3,  2005,  Advanced  Magnetics,  Inc.  and  Cytogen  Corporation
  announced that the U.S. Food and Drug Administration's  Oncologic Drugs Advisory
  Committee  (ODAC)  voted  15 to 4 to not  recommend  approval  of  the  proposed
  indication  for  Combidex(R),  Advanced  Magnetics'  investigational  functional
  molecular  imaging  agent.  In making its  recommendation,  the committee  cited
  insufficient  clinical data to support a broad indication for use of Combidex to
  differentiate  metastatic  from  non-metastatic  lymph  nodes  across all cancer
  types.
  
       Combidex  (ferumoxtran-10)  consists of iron oxide nanoparticles for use in
  conjunction with magnetic resonance imaging (MRI) to aid in the  differentiation
  of cancerous from non-cancerous lymph nodes.
  
       Combidex received an approvable letter, subject to certain conditions, from
  the FDA in June 2000. In September 2004, Advanced Magnetics submitted a complete
  response to the approvable letter. A decision by the FDA on Combidex is expected
  by the FDA-designated user fee goal date of March 30, 2005.
  
       The full text of the March 3, 2005 press release issued in connection  with
  the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K,
  and is incorporated herein by reference.  The foregoing description is qualified
  in its entirety by reference to such Exhibit.
  
  ITEM 9.01   FINANCIAL STATEMENTS AND EXHIBITS
  
  (c) Exhibits.
  
       Exhibit No.       Description
       -----------       -----------
           99.1          Press Release  of Advanced  Magnetics and  Cytogen  dated
                         March 3, 2005
  SIGNATURES
  
       Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
  Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
  undersigned hereunto duly authorized.
  
                                      CYTOGEN CORPORATION
  
                                      By:  /s/ William J. Thomas
                                         -----------------------------------------
                                         William J. Thomas
                                         Senior Vice President and General Counsel
  
  Dated:   March 3, 2005
  EXHIBIT INDEX
  
       Exhibit No.       Description
       -----------       -----------
           99.1          Press  Release of Advanced  Magnetics and  Cytogen  dated
                         March 3, 2005